Rykov S. A., Shargorodska I. V., Lavryk N. S., Kornilov L. V

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

In recent years, an increase in metabolic lesions of the cornea of the cornea with destructive corneal lesions (DCL) has been observed on the background of conservative treatment using pathogenetically oriented drugs and drugs of symptomatic action. It is known that dystrophic processes in the cornea progress, causing profound tissue destruction, pain syndrome, significantly reducing function. Keratoplasty surgical interventions that are effectively used to treat this pathology are associated with problems with the use of donor material. This increases the significance of the use of metabolic therapy, aimed at optimizing antioxidant processes. However, effectiveness must be determined by evaluating clinical observations. Thus, when forming a list of medicines for conservative treatment of DCL, it is advisable to conduct a comparative study of the effectiveness of drugs for local application, namely: stimulators of reparative processes and metabolism, moisturizers, antibiotics. Objective. To study the effectiveness of local application of modern available drugs – stimulators of reparative processes and metabolism, broad-spectrum antibiotics in the treatment of destructive processes of the cornea. The object and methods of research. The study was conducted in parallel groups of patients with keratopathy (DCL). Evaluated the dynamics of objective clinical changes, which characterized the reparative processes in the cornea. The control was 10 eyes 7 patients with destructive corneal lesions (DCL) without the use of additional drugs for stimulation of reparation. To assess the eye condition, the Clinical Symptom Expression Index (CSEI) in eyeballs was used. The efficacy of treatment was defined as the percentage of cured patients (significant improvement) and the disappearance of destructive lesions (erosion) of the cornea. Thus, in patients with purulent DUR, broad-spectrum antibiotics of local use, namely: Oftaquix (“Santen”) and Ciloxan (“Alcon”), have a pronounced anti-inflammatory effect. Recovery time from 3 to 5 days in 56% and 38% of cases respectively, 44% of eyes in 5 days required further treatment due to the presence of destruction of the epithelial layer of the cornea. In assessing the effectiveness of the metabolic therapy options used in DUR to stimulate epithelization and healing of the cornea, it has been found that the use of corneoprotective Dexpanthenol (Corneregel “Baush + Lomb”) in combination with vitamin preparation resulted in improvement in 96% of eyes (control of 70%), with the appointment of 0.5% solution of Cyclosporin (Restasis), recovery is noted in 75% of cases in 30 days. Significant changes in reparation (epithelization) were not detected in 25% of severe DCL cases. Significant improvement in 75% of cases was noted with trehalose hyaluronic acid (Laboratoires Thea Tealoz Duo), but in 25% of cases no adequate repair was noted. Thus, broad-spectrum antibiotics, fluoroquinolones of local application, namely: Oftaquix (“Santen”) and Ciloxan (“Alcon”) have a clear anti-inflammatory action in patients with purulent DCL and well tolerated by patients. It has been noted that more than 44% of the 5 days of antibiotic therapy required further treatment due to the destruction of the epithelial layer of the cornea. Thus, with the conservative treatment of DCLs, the recommended use of drugs for 5-7 days followed by a determination of indications for surgical treatment.Conclusions 1. In patients with purulent DCL antibiotics of a wide range of local application, namely: Oftaquix (“Santen”) and Ciloxan (“Alcon”) have a clear anti-inflammatory action. Recovery time from 3 to 5 days in 56% and 38% of cases respectively, 44% of eyes in 5 days required further treatment due to the destruction of the epithelial layer of the cornea. 2. In patients with DCL, when assessing the effectiveness of metabolic therapy options for corneal reparation, it was determined that use of the corneoprotector Dexpanthenol (Corneregel “Baush+Lomb”) in combination with the vitamin preparation resulted in improvement in 96% of the eyes (control of 70%) (p < 0.05). 3. In the eyes with the DCL, a significant improvement in 75% of cases was noted with Trehalose Hyaluronic Acid (Laboratoires Thea Tealoz Duo) treating, but in 25% of cases, no adequate repair was noted. Improvement is associated with a positive effect on eye moisturizing. 4. In the group of patients with DCL receiving 0.5% solution of Cyclosporine (Restasis, “Allergan”), cure was noted in 75% of cases (8 eyes) for 30 days. Significant changes in reparation (epithelization) are not defined in 25% of severe cases of DCL. 5. Comparison of the time of reduction of the clinically significant score (CSEI) by 50% – Dexpanthenol with Taufon – 7 days – 5.1 points (P <0.05), Trehalose Hyaluronic acid – 14 days – 7.9 points (P <0.05), 0.5% Cyclosporine – 14 days – 5.7 points (P <0.05), gentamicin – 5 days – 6.6 points (P <0.05), Cyfloxane – 5 day – 5.9 points (P <0.05), Oftaquix – 5 days -3.7 points (P <0.05). 6. With the conservative treatment of DCL, the recommended use of drugs for 5-7 days with further determination of indications for surgical treatment.

destructive corneal lesions, metabolic therapy, Corneregel, Tealoz Duo, Restasis, Oftaquix, Ciloxan.

1. Yefimova YuV, Vitovskaya OP. Efektivnost primeneniya ftorkhinolonov v lecheniyi keratitov. Arhiv Oftalmologii Ukrainy. 2015;1(2):65-8. [in Russian].
2.  Pavliuchenko KP, Mogilevskiy SYu, Tereshchenko YuN, Zykov IG. Aktivniye podhody v lecheniyi bakterialnyh keratitov s gnoynyh yazv rogovitsy. Arhiv Oftalmologii Ukrainy. 2013;1(1):120-7. [in Russian].
3. Maychuk YuF. Lecheniye katarakty s metabolicheskih porazheniy rogovitsy. «Consilium medicum». 2004;3(5):60. [in Russian].
4. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716-26.
5. Tripathi BJ, Tripathi RC. Cytotoxic effects of benzalkonium chloride and chlorobutanol on human corneal epithelial cells in vitro. Lens Eye Toxic Res. 1989;6:395-403.
6.  Lavrik NS. Metabolicheskaya terapiya pri narusheniyah reparativnyh protsessov v rogovoy obolochke. Mezhdunarodniy nauchno-prakticheskiy zhurnal. Oftalmologiya Vostochnaya Evropa. Professionalnye izdaniya. 2013;2(17):62-6. [in Russian].
7.  Aragona P, Di Stefano G, Ferreri F, Spinella R, Stilo A. Sodium hyaluroante eye drops of different osmolarity for the treatment of dry eye in Sjögren’s syndrome patients. Br. J. Ophthalmol. 2002;86:879-84.
8. Burstein NL. Cornea l cytotoxicity of topically applied drugs, vehicles and preservatives. Surv. Ophthalmol. 1980;25:15-30.
9. Report of the International Dry Eye Workshop (DEWS). The epidemiology of dry eye disease. Ocul. Surf. 2007;5:27-41.
10. Brzheskiy VV, Somov YY. Rogovichno-konyunktivalniy kseroz (diagnostika, klinika, lechenie). S.-Peterburg; 2003. 142 s. [in Russian].
11.  Rossi GC. Managment of ocular surface disease in patients with glaucoma. Ophthalmology inter. 2013;8(2):54-6.
12. Definition and classification of dry eye. Report of the diagnosis and classification Subcommittee of the Dry Eye Workshop (DEWS). The Ocular Surface. 2007;5(2):75-92.
13. Rossi GC, Tinelli C, Pasinetti GM. Dry eye syndrome-related quality of the life in glaucoma patients. Eur. J. Ophthalmol. 2009;4:572-9.
14.  Baudouin C, Labbe A, Liang H. Preservatives in eye drops: the good, the bad and the ugly. Prog. Retin Eye Res. 2010;29:312-34.
15.  Sullivan BD. Influence of aging on polar and neutral lipid profiles in human meibomiangland secretion. Archives of Ophthalmol. 2006;124:1286- 92.
16.  Sand BB, Marner K, Nom MS. Sodium gyaluronate in the treatment of keratoconjunctivitis sicca. Acta Ophthalmol. 1989;67(2):181-3.
17. Luyckx J, Baudouin C. Tregalose an intriguing disaccharide with potential for medical application in ophthalmology. Clin. Ophthalmol. 2011;5:577-81.
18. Hovakimyan M, Ramoth T, Löbler M, Schmitz KP, Witt M, Guthoff R, et al. Evaluation of protective effects of trehalose on desiccation of epithelian cells in three dimensional reconstructed human corneal epithelium. Curr. Eye Res. 2012;37(11):982-9.
19. Chen W, Zhang X, Liu M, Zhang J, Ye Y, Lin Y, et al. Tregalose protect against ocular surface disorders in experimental murine dry eye througt suppression of apoptosis. Exp. Eye Pres. 2009;89(3):311-9.
20. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321-38.
21.  Skrypnyk RL, Tyhonchuk NA, Shumilina KS. Kliniko-imunologichni osoblyvosti syndromu “suhogo oka” u zhinok z gormonalnoyu disfunktsieyu. Oftalmologichniy zhurnal. 2013;1:47-51. [in Ukranian].
22. Perekrestov MB. Effektivnost primeneniya lechebno-tektonicheskoy keratoplastiki autoskleralnymi loskutami pri gnoynoy yazve rogovitsy [dysertatsiia]. Donetsk; 2011. 173 s. [in Russian].
23. Maycuk YuF. Optimizatsiya farmakoterapii vospalitelnyh bolezney glaznoy poverhnosti. Moskva; 2010. 114 s. [in Russian].
24. O’Brien TP. Bacterial keratitis. Krachmer JH, Mannis MJ, Holland EJ, editors. Cornea and external disease: clinical diagnosis and management. Volume II. St Louis: Mosby-Year Book; 1997. р. 1139-90.
25. Yamada M, Mochizuki H, Yamada K, Kawai M, Mashima Y. Aqueous humour levels of topically applied levofloxacin, norfloxacin and lomefloxacin in the same human eyes. J. Cataract Refract Surg. 2003;29:1771-5.
26.  Sergienko N, Sukhina L, Kovalenko U, Mattias Merzbacher. Hydrocortisone concentration influence time to significant healing of acute inflamation of the ocular surface and adnexa-result from a double-blinde randomized controlled trial. Dorothea Grob. BMC Ophthalmology. 2014;14:64. Available from: http//www.biomedcentral.com/1471-2415/14/64

«Bulletin of problems biology and medicine» Issue 1 Part 2 (149), 2019 year, 175-181 pages, index UDK 617.713-002.447:617.715.8-089.85

10.29254/2077-4214-2019-1-2-149-175-181